Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.

Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwé C, Jansen M, Gerver WJ, Waelkens J, Drop S

Archives of disease in childhood1 Oct 1996Cited by 90 (Europe PMC)

PMID8984913PMCIDPMC1511728DOI10.1136/adc.75.4.292PepBankPUB-08984913

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, bone maturation slowed during triptorelin treatment.
In plain wordsIn children with early puberty, bone maturation slowed during triptorelin treatment compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone maturation during treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
The rate of bone maturation decreased during treatment
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491301
02HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, predicted adult height increased from 158.2 to 163.9 cm during triptorelin treatment.
In plain wordsIn children with early puberty, predicted adult height increased during triptorelin treatment compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height at treatment end
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Predicted adult height
158.2 cm
start of treatment
Predicted adult height
163.9 cm
end of treatment
Source sentences
Summary
the predicted adult height increased from 158.2 (7.4) cm to 163.9 (7.5) cm at the end of treatment (p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491302
03HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, bone maturation accelerated after triptorelin withdrawal.
In plain wordsIn children with early puberty, bone maturation accelerated after triptorelin withdrawal compared with during treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBone maturation after withdrawal
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
When treatment was stopped bone maturation accelerated
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491303
04HumanNon-randomized trialEfficacy outcome
In children treated with triptorelin for central precocious puberty, final height was 161.6 cm, above the pretreatment prediction.
In plain wordsIn children treated with triptorelin for early puberty, final height exceeded the pretreatment prediction.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFinal height versus baseline prediction
Study
n: not reported in source
Comparator
Predicted adult height at the start of treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Final height
161.6 cm
after triptorelin treatment
Source sentences
Summary
When treatment was stopped bone maturation accelerated, resulting in a final height of 161.6 (7.0) cm, which was higher than the predicted adult height at the start of treatment (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491304
05HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, body mass index increased during triptorelin treatment and remained high at treatment cessation.
In plain wordsIn children with early puberty, body mass index increased during triptorelin treatment and remained high when treatment stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
Body mass index increased during treatment and remained high on cessation.
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491305
06HumanNon-randomized trialEfficacy outcome
In children previously treated with triptorelin, the sitting-height to subischial-leg-length ratio was normal at final height.
In plain wordsIn children previously treated with triptorelin, body proportions were normal at final height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedBody proportions at final height
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
At final height, the ratio of sitting height to subischial leg length was normal.
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491306
07HumanNon-randomized trialEfficacy outcome
In girls previously treated with triptorelin, menarche occurred at 12.3 years and a median 1.1 years after withdrawal.
In plain wordsIn girls previously treated with triptorelin, periods began at 12.3 years and a median 1.1 years after withdrawal.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedMenarche after treatment
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Age at menarche
12.3 years
girls previously treated with triptorelin
Time from treatment stop to menarche (median)
1.1 years
girls previously treated with triptorelin
Time from treatment stop to menarche (range)
0.4 to 2.6 years
girls previously treated with triptorelin
Source sentences
Summary
Menarche occurred at 12.3 (1.1) years, and at a median (range) of 1.1 (0.4 to 2.6) years after treatment was stopped.
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491307
08HumanNon-randomized trialSafety outcome
In girls previously treated with triptorelin, ovaries were normal on pelvic ultrasonography.
In plain wordsIn girls previously treated with triptorelin, pelvic ultrasound showed normal ovaries.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedOvarian ultrasonography
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
The ovaries were normal on pelvic ultrasonography.
2 context sentences(design, population, supporting numbers)
Summary · context
31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks.
Summary · context
Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped.
Report a problemFND-0898491308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.